The SWI/SNF Complex and ARID1A: Disease Context and Target Biology
The SWI/SNF chromatin remodeling complex is mutated in approximately 20% of all human cancers, making it one of the most frequently disrupted tumour suppressor machineries in oncology. Within this complex, ARID1A — also designated BAF250a or p270 — is the subunit exclusive to the canonical BAF (cBAF) variant and carries the highest mutation frequency of any SWI/SNF component, with alteration rates reaching up to 50% in ovarian clear-cell carcinoma (CCC).
ARID1A mutations have been documented across a broad spectrum of malignancies: ovarian CCC, endometrioid carcinoma, uterine carcinoma, gastric cancer, and follicular lymphoma transforming to diffuse large B-cell lymphoma (DLBCL). Foundational biomarker work from the British Columbia Cancer Agency and researchers including David Huntsman documented ARID1A mutations — spanning more than 120 variant alleles — as markers of malignant progression in endometriosis and as predictors of treatment response in CCC and endometrioid carcinoma.
The two catalytic ATPase subunits of the SWI/SNF complex — SMARCA4 (BRG1) and SMARCA2 (BRM) — are the central molecular targets of current drug development efforts. SMARCA4 is frequently mutated in primary solid tumours, including 10–15% of lung adenocarcinomas as well as melanoma, hepatocellular carcinoma, and pancreatic cancer. A landmark 2015 study from Johns Hopkins established that dual loss of SMARCA4 and SMARCA2 is highly specific for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), with SMARCA4 absent in more than 90% of SCCOHT cases examined across more than 3,000 gynaecological tumours.
ARID1A is mutated in up to 50% of ovarian clear-cell carcinomas and the SWI/SNF chromatin remodeling complex is altered in approximately 20% of all human cancers, making it one of the most frequently mutated tumour suppressor systems in oncology.
Synthetic lethality describes a situation where the simultaneous loss of two genes causes cell death, whereas loss of either gene alone is tolerated. In SWI/SNF biology, SMARCA4-deficient cancer cells survive by relying exclusively on the paralogous ATPase SMARCA2. Pharmacologically inhibiting or degrading SMARCA2 in these cells is lethal to the tumour while sparing normal cells that retain functional SMARCA4.
Additional SWI/SNF subunits addressed across the patent and literature landscape include SMARCB1 (BAF47/INI1/SNF5), ARID1B, PBRM1, ARID2, and BRD7 — each representing distinct tumour contexts and therapeutic entry points. A Cornell University filing from 2025 specifically links ARID1A loss-of-function mutations, including the Q474* variant, to follicular lymphoma transformation and vulnerability to SMARCA4/2 pharmacological inhibition, extending the clinical relevance of this biology into haematological malignancies.
SMARCA2 vs SMARCA4: Exploiting Synthetic Lethality with Small-Molecule Antagonists
SMARCA2 antagonists designed to exploit the SMARCA2/SMARCA4 synthetic lethal relationship represent the largest cluster of patent activity in this space. The therapeutic rationale is precise: SMARCA4-deficient cancer cells rely exclusively on SMARCA2 ATPase activity for chromatin remodeling; antagonising SMARCA2 in these cells causes cell cycle arrest, cellular senescence, and increased H3K9me3 levels — a cascade that culminates in tumour cell death.
Epizyme, Inc. has filed the most extensive body of IP in this area, with patent families across US, WO, JP, KR, IL, AU, CA, MX, and BR jurisdictions. Critically, these compounds target the helicase/ATPase domain of SMARCA2 — not the bromodomain — and are designed to lack activity against SMARCA4, preserving normal cell function. One representative chemical series, pyridin-2-one compounds, is documented across multiple jurisdictions in filings spanning 2018 to 2021.
SMARCA2 inhibition is confirmed as synthetic lethal across multiple tumour contexts — NSCLC, ovarian, liver, and haematological cancers — with SMARCA2 knockdown consistently causing cell cycle arrest, increased H3K9me3, and cell death in SMARCA4-null cells. Janssen Pharmaceutica entered the field in 2026 with 1,6-naphthyridine compounds as SMARCA2 inhibitors specifically indicated for SMARCA4-deficient non-small cell lung cancer, signalling continued commercial investment in this target class.
“SMARCA4-deficient cancer cells rely exclusively on SMARCA2 ATPase activity for chromatin remodeling; antagonising SMARCA2 causes cell cycle arrest, senescence, and increased H3K9me3 levels — a cascade that culminates in tumour cell death.”
A Yale University filing from 2025 introduces an important nuance: SMARCA4 can play a pro-growth role in TKI-resistant lung cancer, suggesting context-dependent oncogenic as well as tumour-suppressive functions. This duality underscores the importance of patient stratification and companion diagnostics in any clinical development programme targeting SWI/SNF components, as noted by researchers publishing through Nature and related journals in the epigenomics field.
PROTAC Degraders Displace Classical Inhibitors as the Preferred Modality
PROTAC-based targeted protein degradation has emerged as the dominant modality in SWI/SNF drug discovery from 2022 onwards, with multiple competing structural series now documented in the patent literature. Unlike classical occupancy-driven inhibitors, PROTACs are bifunctional molecules that recruit an E3 ubiquitin ligase to SMARCA2 or SMARCA4, directing the target protein for complete proteasomal destruction — an event-driven mechanism that potentially overcomes residual activity from partial inhibition.
PROTAC-based SMARCA2 and SMARCA4 degraders — including 6-substituted pyridazine compounds from Aurigene Oncology Limited and bifunctional scaffolds from C4 Therapeutics, AstraZeneca, and Prelude Therapeutics — eliminate the target protein entirely through proteasomal destruction, offering event-driven pharmacology that potentially overcomes residual activity from partial catalytic inhibition.
Structurally diverse degrader scaffolds are now documented across multiple assignees: 6-substituted pyridazine compounds (Aurigene Oncology Limited, IL and ID filings, 2023), 3-substituted pyridazine compounds (Aurigene Oncology Limited, CN filing, 2024), and generic PROTAC structures from C4 Therapeutics (CN, 2025), Dana-Farber Cancer Institute (CN, 2024), AstraZeneca (CN, 2026), Kymera Therapeutics (AR, 2024), Prelude Therapeutics (CN and KR, 2025), and Sichuan University (CN, 2025). The breadth of this activity — spanning both commercial and academic assignees across North America, Europe, and China — signals that PROTAC degraders for SWI/SNF targets have become a global priority.
Search the full SMARCA2 and SMARCA4 degrader patent landscape with PatSnap Eureka’s AI-powered analysis tools.
Explore PROTAC Patent Data in PatSnap Eureka →IP differentiation between these programmes will likely hinge on two axes: selectivity profile (SMARCA2-only versus dual SMARCA2/4 degradation) and novelty of E3 ligase recruitment strategy. Aurigene’s responder identification methods — which link SWI/SNF complex function to androgen receptor signalling in prostate cancer cell lines including VCaP and LNCaP, with defined tumour-specific alteration profiles including PTEN mutation, AR dependence, and TMPRSS2-ERG fusion — represent one approach to narrowing the patient population and strengthening IP position through companion diagnostic co-development.
The shift toward degraders also reflects a broader industry trend toward event-driven pharmacology documented by organisations including NIH and academic drug discovery programmes globally. The emergence of Sichuan University and Fudan University as academic filers in the SMARCA2/4 degrader and SMARCA4 immunology spaces respectively signals growing China-based institutional activity in this area.
EZH2 and ATR Inhibitors: Orthogonal Routes into SWI/SNF-Deficient Tumours
Two distinct inhibitor classes — EZH2 inhibitors targeting the PRC2 axis and ATR kinase inhibitors exploiting replication stress — provide orthogonal therapeutic entry points into SWI/SNF-deficient cancers, with the EZH2 approach carrying the most mature translational evidence in the retrieved dataset.
EZH2 Inhibitors and the PRC2/SWI/SNF Antagonism
SWI/SNF and polycomb repressive complex 2 (PRC2/EZH2) are known functional antagonists: when SMARCA4 is lost through mutation, EZH2 activity is unopposed and deposits H3K27me3 at the SMARCA2 promoter, silencing its expression. EZH2 inhibitors can reverse this silencing, reactivate SMARCA2, and restore differentiation programmes in SMARCB1-deficient rhabdoid tumours and SMARCA4-deficient SCCOHT. Genentech filings explicitly link H3K27me3 occupancy at the SMARCA2 promoter as a mechanistic biomarker for EZH2 inhibitor response in SMARCA4-mutant cells.
In SMARCA4-mutant cancer cells, EZH2 deposits H3K27me3 at the SMARCA2 promoter, silencing SMARCA2 expression. EZH2 inhibitors can reverse this silencing and restore differentiation. Genentech patent filings identify H3K27me3 occupancy at the SMARCA2 promoter — not ARID1A mutation status alone — as the more precise predictive biomarker for EZH2 inhibitor response.
A critical finding from Genentech’s US patent (2021) is that ARID1A mutation alone is insufficient to predict EZH2 inhibitor response: ARID1A-mutant cell lines A2780 are described as sensitive controls, while Hec-1A and SK-OV-3 (also ARID1A-mutant) are described as insensitive to EPZ-6438 (tazemetostat). This finding — corroborated by the broader epigenomics literature accessible through WIPO-indexed patent databases — underscores the need for H3K27me3 chromatin occupancy as a companion biomarker rather than reliance on genomic mutation status alone.
The strongest clinical signal in the retrieved dataset comes from an Epizyme CN patent (2022) describing a case report of a 27-year-old woman with SMARCA4-negative MRTO/SCCOHT treated with tazemetostat 1600 mg twice daily for 8 weeks, with radiographic imaging presented as evidence of clinical activity. Epizyme’s EZH2 inhibitor tazemetostat is also described in the context of MRTO/SCCOHT treatment more broadly, and Daiichi Sankyo has developed EZH1/2 dual inhibitors with reported greater antitumour efficacy in preclinical models.
ARID1A mutation status alone is insufficient to predict EZH2 inhibitor sensitivity. Retrieved Genentech data show that some ARID1A-mutant cell lines (Hec-1A, SK-OV-3) are insensitive to EPZ-6438 (tazemetostat), while others (A2780) are sensitive. H3K27me3 enrichment at the SMARCA2 promoter is proposed as a more precise predictive biomarker for patient selection.
ATR Kinase Inhibitors and ARID1A-Dependent Replication Stress
A mechanistically distinct synthetic lethal opportunity is provided by ATR (ataxia telangiectasia mutated and Rad3-related protein kinase) inhibitors. Patents from Breast Cancer Now and the Institute of Cancer Research describe ATR inhibitors as synthetic lethal agents specifically active in BAF complex-deficient cancers, with ARID1A identified as the primary ATRi synthetic lethal biomarker from large-scale genetic screens. The proposed mechanism is that ARID1A/BAF deficiency creates replication stress or DNA repair vulnerabilities that increase dependence on ATR-mediated checkpoint signalling — a rationale that the Institute of Cancer Research has framed as supporting IND-enabling study designs, as documented in their WO (2017) and AU (2018) filings.
According to EPO patent records, the ATR inhibitor family from Breast Cancer Now and the ICR spans WO, AU, and JP jurisdictions (2017–2022), establishing a foundational IP position for ARID1A as a “clinically useful biomarker” for ATRi sensitivity. No clinical trial results are cited in the retrieved records for this modality.
Emerging Combinations and the Convergence with KRAS and TKI Resistance
The most strategically significant recent development in SWI/SNF-targeted oncology is the emergence of combination strategies that connect chromatin remodeling biology to two of the most commercially important resistance mechanisms in solid tumour oncology: KRAS G12C inhibitor resistance and EGFR TKI resistance.
Prelude Therapeutics filed patents in CN, KR, and BR jurisdictions in 2025 describing the combination of selective SMARCA2 degraders with KRAS-targeting therapies — specifically KRAS G12C inhibitors — for SMARCA4-null cancers. The rationale is to overcome acquired resistance to KRAS G12C inhibitors by co-targeting SMARCA2, which SMARCA4-null cells depend upon for survival. This positions SMARCA4-null NSCLC as a convergence point between two major oncology IP landscapes, creating potential licensing and co-development opportunities.
Map the emerging combination strategy patent landscape across SMARCA2, KRAS, and TKI resistance with PatSnap Eureka.
Analyse Combination Strategies in PatSnap Eureka →A Yale University filing (WO, 2025) describes mSWI/SNF complexes as retargeted genome-wide in TKI-resistant lung cancer, signalling that SWI/SNF inhibition — including SMARCA4 inhibition — can reverse osimertinib resistance in a subset of EGFR-mutant NSCLC models. These combination signals represent high-value IP territory that is newly filed and potentially uncrowded.
Additional emerging combination directions documented in the retrieved dataset include:
- CBP/p300 inhibition in SWI/SNF-deficient cancers: Sumitomo Pharma (US, 2024) identifies CBP/p300 inhibitors as a therapeutic strategy in BAF complex-dysfunction cancers including ARID-deficient tumours, pointing to convergent chromatin writer targeting.
- G-quadruplex binding ligands: The Institute of Cancer Research (GB, 2025) describes G-quadruplex binding ligands as synthetic lethal agents in ARID1A- or SMARCA4-deficient cancers — a structurally novel modality not previously prevalent in the SWI/SNF-focused dataset.
- SMARCA2 degrader + androgen pathway: Aurigene’s prostate cancer responder identification strategies link SWI/SNF complex function with AR signalling (PTEN deletion, TMPRSS2-ERG fusion), signalling that combination with enzalutamide or other AR-targeting agents may be viable for castration-resistant prostate cancer.
- eEF2 / mRNA translation elongation inhibition: A Fred Hutchinson Cancer Center patent (US, 2024) describes inhibiting eukaryotic elongation factor 2 (eEF2) as a strategy for ARID1A-mutant and SWI/SNF-mutant cancers — a mechanistically distinct, non-epigenetic approach.
- Mithramycin analogues: The Children’s Hospital of Philadelphia describes mithramycin analogue EC-8042 for rhabdoid cancers bearing SMARCB1 mutations, acting on residual SWI/SNF redistribution toward super-enhancers.
Prelude Therapeutics filed patents in 2025 describing the combination of selective SMARCA2 degraders with KRAS G12C inhibitors for SMARCA4-null cancers, to overcome acquired KRAS G12C inhibitor resistance. Separately, a Yale University 2025 filing signals that SWI/SNF inhibition can reverse osimertinib resistance in EGFR-mutant NSCLC models, positioning SMARCA4-null NSCLC as a convergence point between two major oncology drug resistance landscapes.
Assignee Landscape and Strategic IP Implications for Drug Developers
Innovation activity in chromatin remodeling inhibitors for ARID1A-mutant cancers is heavily patent-driven, with commercial IP dominating over academic literature in the retrieved dataset. Epizyme, Inc. is the most prominently represented assignee, with at least 12 distinct patent families across US, WO, JP, KR, IL, AU, CA, MX, and BR jurisdictions covering SMARCA2 antagonists, SMARCA4 inhibitors, EZH2 inhibitors, and patient stratification methods, with activity spanning 2018 to 2024.
Aurigene Discovery Technologies Limited / Aurigene Oncology Limited holds multiple families across WO, US, CA, SG, KR, JP, MX, IL, ID, and BR jurisdictions covering SMARCA2/4 degraders and responder identification methods, with a prostate cancer focus and an active filing period from 2021 to 2024. Newer entrants with PROTAC/degrader-focused IP include C4 Therapeutics (CN, 2025), AstraZeneca (CN, 2026), Prelude Therapeutics (CN, KR, BR, 2025), and Kymera Therapeutics (AR, 2024).
Academic and institutional assignees play a critical biomarker-establishing role: British Columbia Cancer Agency Branch, Martin Hirst, and David Huntsman hold foundational ovarian CCC ARID1A biomarker patents (WO 2011, US 2013, EP 2013). Memorial Sloan Kettering Cancer Center and The Translational Genomics Research Institute / University of British Columbia hold SCCOHT-defining IP. Dana-Farber Cancer Institute holds key mechanistic patents on non-canonical SWI/SNF complexes (WO, US; 2020–2024) and SMARCA4-targeting bifunctional compounds. Genentech holds diagnostic and therapeutic patents linking SMARCA2 expression and H3K27me3 occupancy to EZH2 inhibitor response (US, JP; 2019–2021).
“Drug developers entering this space must navigate a dense patent landscape across degrader scaffolds (pyridazines, PROTACs) and small-molecule inhibitors targeting helicase/ATPase domains — IP differentiation will likely hinge on selectivity profiles and novel E3 ligase recruitment strategies.”
Three strategic implications stand out from the assembled evidence. First, ARID1A mutation status is the most tractable patient stratification biomarker in this dataset, supported by foundational patents and operationalised in newer filings linking ARID1A genotype to ATR inhibitor, EZH2 inhibitor, and elesclomol sensitivity — making companion diagnostic co-development a priority for any clinical programme. Second, the EZH2 inhibitor/SWI/SNF deficiency axis carries the most mature translational evidence, with a documented clinical observation in SCCOHT and established mechanistic pathways. Third, SMARCA4-null NSCLC is emerging as a convergence point for SWI/SNF biology, KRAS resistance, and EGFR TKI resistance — a newly filed (2025) and potentially uncrowded IP territory that warrants close monitoring. PatSnap’s PatSnap Eureka platform enables real-time tracking of these filing patterns across all major jurisdictions.
The growing presence of Sichuan University and Fudan University as academic filers in degrader and immunology sub-spaces respectively, alongside Janssen’s recent entry with 1,6-naphthyridine SMARCA2 inhibitors (CN, 2026), signals that the competitive intensity of this field will continue to increase. Researchers and business development teams should also note that the PatSnap resources library maintains updated analyses of SWI/SNF and epigenetic oncology patent landscapes.